BXA0.F LAVIPHARM S.A. NA EO 1

Healthcare Pharmaceuticals Frankfurt Exchange
1.41 EUR
Close of Nov 11, 2026
0.7115 1.82
Market cap
EUR 241M
P/E
47.0x
P/B
4.27x
ROE
10.6%
Dividend yield
1.40%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is BXA0.F undervalued?

Graham number
Price1.41
Graham value0.4722
Premium198.6%

BXA0.F trades 198.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

LAVIPHARM S.A. NA EO 1 fundamental analysis

No fundamental analysis for LAVIPHARM S.A. NA EO 1 yet.

LAVIPHARM S.A. NA EO 1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About LAVIPHARM S.A. NA EO 1

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company w…

Full company profile